GLP-1 Market
LLY $1415.87 ▲ +0.3% NVO $40.42 ▼ -2.3% PFE $29.07 ▼ -0.5% VKTX $29.19 ▲ +0.7% KLRA $13.80 ▲ +0.8% GPCR $21.25 ▼ -0.7% RHHBY $61.32 ▲ +3.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

THP-00101

THP-00101

Company
THPharm Corp.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 10, 2026

Trial details
  • Status unknown NCT NCT04255238

    A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

    Not yet reported LG Chem 468 participants Est. completion 2022-12-30
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06063109

    A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.

    Not yet reported THPharm Corp. 51 participants Est. completion 2023-11-09 1 site Stand-alone
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
  • Active, not recruiting NCT NCT06647745

    A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

    Not yet reported THPharm Corp. 222 participants Est. completion 2027-01-28 2 sites Stand-alone
    Type 2 diabetes Other conditions: Hypertension
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: THP-00101, Forxiga Tab.

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.